- Home
- LPSN vs ICCM Comparison
LPSN vs ICCM Comparison
Compare LPSN & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPSN | ICCM |
|---|---|---|
| Founded | 1995 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 43.4M |
| IPO Year | 2000 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LPSN | ICCM |
|---|---|---|
| Price | $3.00 | $0.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 92.8K | ★ 150.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $249,838,000.00 | N/A |
| Revenue This Year | N/A | $19.87 |
| Revenue Next Year | N/A | $31.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.54 |
| 52 Week High | $7.54 | $1.53 |
Technical Indicators
Market Signals| Indicator | LPSN | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 49.66 |
| Support Level | $2.94 | $0.59 |
| Resistance Level | $4.23 | $0.62 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 46.32 | 45.76 |
Price Performance
Historical ComparisonAbout LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.